• Designed and implemented IP strategy for 9 FDA-approved drugs and 60 active clinical trials

Imbruvica, Erleada, Lesinurad, Otiprio, Xiidra, Talazoparib, Maralixibat, and Tyrvaya

• Extensive experience representing clients on both sell-side and buy-side M&As with six over $1 billion

Synthorx, Vividion Therapeutics, Lengo Therapeutics, Amplyx Pharmaceuticals, Abide Therapeutics, Aragon Pharmaceuticals, Ardea Biosciences, Pharmacyclics, and Seragon Pharmaceuticals, each leading to an acquisition by a major pharmaceutical company.

Amicus Therapeutics, Denali Therapeutics, and United Therapeutics in various intellectual property matters, including acquisitions.

• Extensive experience representing underwriters, investors, and companies in financings
  
  General Atlantic Service Company, SR One Capital Management, RA Capital Management, New Enterprise Associates (NEA), Vida Ventures, OrbiMed, Frazier Healthcare Partners, venBio Partners, Foresite Capital, Novo Holdings, Coi Pharmaceuticals, Adjuvant Capital, Foundation Fighting Blindness, and other venture and investment funds, in IP diligence matters.

Have supported more than 100 clients undergoing IP diligence for a venture round of investment

Tenaya Therapeutics, Erasca, Ventyx BioSciences, Acumen Pharmaceuticals, Centessa Pharmaceuticals, Design Therapeutics, Janux Therapeutics, ORIC Pharmaceuticals, Avidity Biosciences, Ambrx, Kinnate Biopharma, Denali Therapeutics, Crinetics Pharmaceuticals, Synthorx, TCR2, and Harpoon Therapeutics, all on IP matters related to their IPOs.

• Connects Life Sciences Community
  
  Co-creator of Wilson Sonsini’s Healthcare Investment Initiative, which includes the Healthcare Investment Forum and the Innovator’s Edge Series. Also on the board of directors for LaunchBio.